L3VLUP
ProSign in

VRTX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VRTXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VRTX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterVRTXGILD
Q3 202031 holders, $21.9bn25 holders, $14.2bn
Q4 202030 holders, $18.4bn27 holders, $13.4bn
Q1 202131 holders, $15.4bn24 holders, $14.5bn
Q2 202130 holders, $12.7bn18 holders, $14.9bn
Q3 202135 holders, $10.1bn20 holders, $16.4bn
Q4 202128 holders, $12.4bn20 holders, $16.8bn
Q1 202223 holders, $16.1bn28 holders, $13.2bn
Q2 202225 holders, $18.1bn26 holders, $13.6bn
Q3 202222 holders, $18.4bn24 holders, $13.3bn
Q4 202228 holders, $18.4bn32 holders, $21.1bn
Q1 202326 holders, $21.4bn27 holders, $21.8bn
Q2 202327 holders, $24.7bn24 holders, $20.7bn
Q3 202333 holders, $24.3bn24 holders, $20.0bn
Q4 202332 holders, $28.6bn22 holders, $21.5bn
Q1 202431 holders, $29.8bn30 holders, $20.3bn
Q2 202429 holders, $33.4bn28 holders, $18.5bn
Q3 202427 holders, $33.5bn29 holders, $24.2bn
Q4 202426 holders, $28.5bn28 holders, $25.9bn
Q1 202521 holders, $35.4bn33 holders, $32.0bn
Q2 202521 holders, $32.3bn27 holders, $30.9bn
Q3 202522 holders, $25.9bn23 holders, $29.4bn
Q4 202526 holders, $31.8bn25 holders, $34.3bn
Q1 202625 holders, $31.8bn25 holders, $38.5bn
Q2 202626 holders, $34.6bn26 holders, $34.2bn
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
GILD

Gilead Sciences Inc

Holders
22
Reported value
$21.5bn
Buyers
10
Sellers
11

Breadth -1 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2023

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VRTX (13)

ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Farallon Capital Management LLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, PDT Partners LLC, Tudor Investment Corp, Two Sigma Investments LP, Voloridge Investment Management LLC, Winton Group Ltd

Only GILD (3)

Arrowstreet Capital LP, Dodge & Cox, Schonfeld Strategic Advisors LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →